参考文献[1]
KUSAMAS，SPRATTJ S，DONEGANW L，et al. The cross rates of growth of human mammary carcinoma[J]．Cancer，1972，30（2）：594-599．.
[2]
FRIBERGS，MATTSONS.On the growth rates of human malignant tumors：implications for medical decision making[J]．J Surg Oncol，1997，65（4）：284-297．.
[3]
DUFFYS W，CHENH H，TABARL，et al. Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase[J]．Stat Med，1995，14（14）：1531-1543．.
[4]
LEES，HUANGH，ZELENM.Early detection of disease and scheduling of screening examinations[J]．Stat Methods Med Res，2004，13（6）：443-456．.
[5]
TAGHIPOURS，BANJEVICD，MILLERA B，et al. Parameter estimates for invasive breast cancer progression in the Canadian National Breast Screening Study[J]．Br J Cancer，2013，108（3）：542-548．.
[6]
LAIM S，YENM F，KUOH S，et al. Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases：Taiwan multicentre cancer screening （TAMCAS）[J]．Int J Cancer，1998，78（1）：21-26．.
[7]
WUJ C Y，HAKAMAM，ANTTILAA，et al. Estimation of natural history parameters of breast cancer based on non-randomized organized screening data：subsidiary analysis of effects of inter-screening interval，sensitivity，and attendance rate on reduction of advanced cancer[J]．Breast Cancer Res Treat，2010，122（2）：553-566．.
[8]
TANK H，SIMONELLAL，WEEH L，et al. Quantifying the natural history of breast cancer[J]．Br J Cancer，2013，109（8）：2035-2043．.
[9]
WUY Y，YENM F，YUC P，et al. Risk assessment of multistate progression of breast tumor with state-dependent genetic and environmental covariates[J]．Risk Anal，2014，34（2）：367-379．.
[10]
FRYBACKD G，STOUTN K，ROSENBERGM A，et al. The Wisconsin breast cancer epidemiology simulation model[J]．J Natl Cancer Inst Monogr，2006（36）：37-47．.
[11]
ALAGOZO，ERGUNM A，CEVIKM，et al. The University of Wisconsin Breast Cancer Epidemiology Simulation Model：an update[J]．Med Decis Making，2018，38（1_suppl）：99S-111．.
[12]
WONGI O，KUNTZK M，COWLINGB J，et al. Cost effectiveness of mammography screening for Chinese women[J]．Cancer，2007，110（4）：885-895．.
[13]
KIMJ K，KIMH D，JUNM J，et al. Correction to：tumor volume doubling time as a dynamic prognostic marker for patients with hepatocellular carcinoma[J]．Dig Dis Sci，2017，62（11）：3259．.
[14]
KIMJ K，KIMH D，JUNM J，et al. Tumor volume doubling time as a dynamic prognostic marker for patients with hepatocellular carcinoma[J]．Dig Dis Sci，2017，62（10）：2923-2931．.
[15]
SABRAM M，SHERMANE J，TUTTLER M.Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic，follicular cell-derived thyroid carcinoma[J]．Cancer，2017，123（15）：2955-2964．.
[16]
WEEDON-FEKJAERH，LINDQVISTB H，VATTENL J，et al. Breast cancer tumor growth estimated through mammography screening data[J]．Breast Cancer Res，2008，10（3）：R41．.
[17]
TAGHIPOURS，CAUDRELIERL N，MILLERA B，et al. Using simulation to model and validate invasive breast cancer progression in women in the study and control groups of the Canadian National Breast Screening StudiesⅠandⅡ[J]．Med Decis Making，2017，37（2）：212-223．.
[18]
BREKELMANSC T，WESTERSP，FABERJ A，et al. Age specific sensitivity and sojourn time in a breast cancer screening programme （DOM） in The Netherlands：a comparison of different methods[J]．J Epidemiol Community Health，1996，50（1）：68-71．.
[19]
TABARL，FAGERBERGG，CHENH H，et al. Efficacy of breast cancer screening by age.New results from the Swedish Two-County Trial[J]．Cancer，1995，75（10）：2507-2517．.
[20]
PACIE，DUFFYS W.Modelling the analysis of breast cancer screening programmes：sensitivity，lead time and predictive value in the Florence District Programme （1975—1986）[J]．Int J Epidemiol，1991，20（4）：852-858．.
[21]
JIANGH，WALTERS D，BROWNP E，et al. Estimation of screening sensitivity and sojourn time from an organized screening program[J]．Cancer Epidemiol，2016，44：178-185．.
[22]
TABBANEF，BAHIJ，RAHALK，et al. Inflammatory symptoms in breast cancer.Correlations with growth rate，clinicopathologic variables，and evolution[J]．Cancer，1989，64（10）：2081-2089．.
[23]
KUROISHIT，TOMINAGAS，MORIMOTOT，et al. Tumor growth rate and prognosis of breast cancer mainly detected by mass screening[J]．Jpn J Cancer Res，1990，81（5）：454-462．.
[24]
LUNDGRENB.Observations on growth rate of breast carcinomas and its possible implications for lead time[J]．Cancer，1977，40（4）：1722-1725．.
[25]
VON FOURNIERD，WEBERE，HOEFFKENW，et al. Growth rate of 147 mammary carcinomas[J]．Cancer，1980，45（8）：2198-2207．.
[26]
PEERP G，VAN DIJCKJ A，HENDRIKSJ H，et al. Age-dependent growth rate of primary breast cancer[J]．Cancer，1993，71（11）：3547-3551．.
[27]
OTTENJ D，VAN SCHOORG，PEERP G，et al. Growth rate of invasive ductal carcinomas from a screened 50-74-year-old population[J]．J Med Screen，2018，25（1）：40-46．.
[28]
马恒敏，王乐，石菊芳，等. 乳腺癌自然史模型研究系统评价：现状及构建中国人群特异性模型面临的挑战[J]．中华流行病学杂志，2017，38（10）：1419-1425．.
MAH L，WANGL，SHIJ F，et al. A systematic review of international simulation models on the natural history of breast cancer：current understanding and challenges for Chinese-population-specific model development [J]．Chin J Epidemiol，2017，38（10）：1419-1425．.[29]
FRACHEBOUDJ，GROENEWOUDJ H，BOERR，et al. Seventy-five years is an appropriate upper age limit for population-based mammography screening[J]．Int J Cancer，2006，118（8）：2020-2025．.
[30]
TILANUS-LINTHORSTM M，KRIEGEM，BOETESC，et al. Hereditary breast cancer growth rates and its impact on screening policy[J]．Eur J Cancer，2005，41（11）：1610-1617．.
[31]
TILANUS-LINTHORSTM M，OBDEIJNI M，HOPW C，et al. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch，United Kingdom，and Canadian magnetic resonance imaging screening trials[J]．Clin Cancer Res，2007，13（24）：7357-7362．.
[32]
KRIEGEM，BREKELMANSC T，BOETESC，et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition[J]．N Engl J Med，2004，351（5）：427-437．.
[33]
BREKELMANSC T，SEYNAEVEC，BARTELSC C，et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk[J]．J Clin Oncol，2001，19（4）：924-930．.
[34]
CAUMOF，VECCHIATOF，STRABBIOLIM，et al. Interval cancers in breast cancer screening：comparison of stage and biological characteristics with screen-detected cancers or incident cancers in the absence of screening[J]．Tumori，2010，96（2）：198-201．.
[35]
BREKELMANSC T，VAN GORPJ M，PEETERSP H，et al. Histopathology and growth rate of interval breast carcinoma.Characterization of different subgroups[J]．Cancer，1996，78（6）：1220-1228．.
[36]
NIXONR M，PHAROAHP，TABARL，et al. Mammographic screening in women with a family history of breast cancer：some results from the Swedish two-county trial[J]．Rev Epidemiol Sante Publique，2000，48（4）：325-331.
[37]
CHENT H，KUOH S，YENM F，et al. Estimation of sojourn time in chronic disease screening without data on interval cases[J]．Biometrics，2000，56（1）：167-172．.
[38]
GENTILIC，SANFILIPPOO，SILVESTRINIR.Cell proliferation and its relationship to clinical features and relapse in breast cancers[J]．Cancer，1981，48（4）：974-979．.
[39]
CHARLSONM E，FEINSTEINA R.Rapid growth rate：a method of identifying node-negative breast cancer patients with a high risk of recurrence[J]．J Chronic Dis，1983，36（12）：847-853．.
[40]
REBBECKT R，LEVINA M，EISENA，et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers[J]．J Natl Cancer Inst，1999，91（17）：1475-1479．.
[41]
WOHLFAHRTJ，ANDERSENP K，MOURIDSENH T，et al. Reproductive history and stage of breast cancer[J]．Am J Epidemiol，1999，150（12）：1325-1330．.
[42]
RYUE B，CHANGJ M，SEOM，et al. Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound[J]．Eur Radiol，2014，24（9）：2227-2235．.
[43]
LEES H，KIMY S，HANW，et al. Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography[J]．Medicine （Baltimore），2016，95（37）：e4874．.
[44]
YOOT K，MINJ W，KIMM K，et al. In vivo tumor growth rate measured by US in preoperative period and long term disease outcome in breast cancer patients[J]．PLoS One，2015，10（12）：e0144144．.
[45]
TABARL，FAGERBERGG，CHENH H，et al. Tumour development，histology and grade of breast cancers：prognosis and progression[J]．Int J Cancer，1996，66（4）：413-419．.
[46]
GUNSOYN B，GARCIA-CLOSASM，MOSSS M.Modelling the overdiagnosis of breast cancer due to mammography screening in women aged 40 to 49 in the United Kingdom[J]．Breast Cancer Res，2012，14（6）：R152．.
[47]
MILLETI，BOUIC-PAGESE，HOAD，et al. Growth of breast cancer recurrences assessed by consecutive MRI[J]．BMC Cancer，2011，11：155．.
[48]
DEMICHELIR，TERENZIANIM，BONADONNAG.Estimate of tumor growth time for breast cancer local recurrences：rapid growth after wake-up? [J]．Breast Cancer Res Treat，1998，51（2）：133-137．.
[49]
FÖRNVIKD，LÅNGK，ANDERSSONI，et al. Estimates of breast cancer growth rate from mammograms and its relation to tumour characteristics[J]．Radiat Prot Dosimetry，2016，169（1/2/3/4）：151-157．.
[50]
HEUSERL，SPRATTJ S，POLKH C.Growth rates of primary breast cancers[J]．Cancer，1979，43（5）：1888-1894．.
[51]
GALANTEE，GALLUSG，GUZZONA，et al. Growth rate of primary breast cancer and prognosis：observations on a 3- to 7-year follow-up in 180 breast cancers[J]．Br J Cancer，1986，54（5）：833-836．.
[52]
TUBIANAM，KOSCIELNYS.Natural history of human breast cancer：recent data and clinical implications[J]．Breast Cancer Res Treat，1991，18（3）：125-140．.
[53]
ABRAHAMSSONL，CZENEK，HALLP，et al. Breast cancer tumour growth modelling for studying the association of body size with tumour growth rate and symptomatic detection using case-control data[J]．Breast Cancer Res，2015，17：116．.
[54]
BATINAN G，TRENTHAM-DIETZA，GANGNONR E，et al. Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis[J]．Breast Cancer Res Treat，2013，138（2）：519-528．.
